Sundaram G. Veerappan
Research Interests
Sundaram G. Veerappan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Barbara M. Ryan
Department of Gastroenterology, Tallaght Hospital, Dublin 24, Ireland
3 shared publications C. A. O’morain
Department of Gastroenterology, Adelaide & Meath Hospital, Tallaght, Dublin 24, Ireland
2 shared publicationsColm A. Oʼmorain
2 shared publicationsBernard Walsh
Gerontology, St James’s Hospital, Dublin 8
1 shared publicationColm A O’morain
1 shared publicationColm A. O’morain
Deparment of Gastroenterology, Adelaide & Meath Hospital, Tallaght, Dublin 24
1 shared publication
Latest Publications
- 1 November 2016
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 28 (11) , 1335-1344
A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients
IFX treatment induced beneficial effects on bone metabolism. Osteoblast culture results suggest that IBD patients may have increased osteoblast viability, but reduced differentiation, which has implications for bone strength.
- 1 November 2016
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 28 (11) , 1335-1344
A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients
IFX treatment induced beneficial effects on bone metabolism. Osteoblast culture results suggest that IBD patients may have increased osteoblast viability, but reduced differentiation, which has implications for bone strength.
- 26 April 2011
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 33 (12) , 1261-1272
Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease
Patients with inflammatory bowel disease (IBD) are at increased risk of osteoporosis. A number of studies have emerged in recent years indicating that tumour necrosis factor (TNF) blockade appears to have a beneficial effect on bone mineral density (BMD) in IBD patients. To provide a review of the available data regarding the effect of the currently licensed anti-TNF-α therapies on bone metabolism and BMD in IBD patients. A Medline search was performed using the search terms 'infliximab', 'bone metabolism', 'IBD', 'BMD', 'bone markers', 'adalimumab', 'bone disease', 'Crohn's disease' and 'ulcerative colitis'. Infliximab has a beneficial effect on bone turnover markers in Crohn's disease (CD) patients in the short term. The longest study to date comprising 24 CD patients showed an overall improvement in two bone formation markers - b-alkaline phosphatase (P = 0.022) and osteocalcin (P = 0.008) at 4 months post-treatment. Moreover, the largest study to date comprising 71 CD patients showed significant improvement in sCTx, a bone resorption marker (P = 0.04) at week-8 post-treatment. There is little data looking at the effect of anti-TNF-α therapy on bone metabolism in ulcerative colitis. Moreover, the long-term effects of anti-TNF-α therapy on bone structure and fracture risk in IBD patients are currently not known. The effect of cessation of anti-TNF-α therapy on bone metabolism is also unknown. Properly controlled long-term trials are needed to fully evaluate the impact of TNF blockade on bone mineral density.
- 26 April 2011
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 33 (12) , 1261-1272
Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease
Patients with inflammatory bowel disease (IBD) are at increased risk of osteoporosis. A number of studies have emerged in recent years indicating that tumour necrosis factor (TNF) blockade appears to have a beneficial effect on bone mineral density (BMD) in IBD patients. To provide a review of the available data regarding the effect of the currently licensed anti-TNF-α therapies on bone metabolism and BMD in IBD patients. A Medline search was performed using the search terms 'infliximab', 'bone metabolism', 'IBD', 'BMD', 'bone markers', 'adalimumab', 'bone disease', 'Crohn's disease' and 'ulcerative colitis'. Infliximab has a beneficial effect on bone turnover markers in Crohn's disease (CD) patients in the short term. The longest study to date comprising 24 CD patients showed an overall improvement in two bone formation markers - b-alkaline phosphatase (P = 0.022) and osteocalcin (P = 0.008) at 4 months post-treatment. Moreover, the largest study to date comprising 71 CD patients showed significant improvement in sCTx, a bone resorption marker (P = 0.04) at week-8 post-treatment. There is little data looking at the effect of anti-TNF-α therapy on bone metabolism in ulcerative colitis. Moreover, the long-term effects of anti-TNF-α therapy on bone structure and fracture risk in IBD patients are currently not known. The effect of cessation of anti-TNF-α therapy on bone metabolism is also unknown. Properly controlled long-term trials are needed to fully evaluate the impact of TNF blockade on bone mineral density.
- 1 July 2009
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 21 (7) , 830-832
Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis
Here we describe a patient with ulcerative colitis who developed alveolitis after infliximab therapy. With earlier case reports of development of alveolitis in rheumatoid arthritis patients after infliximab infusion, the temporal relationship between the infliximab therapy and the development of alveolitis in this case, raises the possibility that the two might be causally related. With an increasing trend towards treating moderate to severely active ulcerative colitis patients with infliximab as a rescue therapy, clinicians should be aware of this potentially serious complication.
- 1 July 2009
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 21 (7) , 830-832
Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis
Here we describe a patient with ulcerative colitis who developed alveolitis after infliximab therapy. With earlier case reports of development of alveolitis in rheumatoid arthritis patients after infliximab infusion, the temporal relationship between the infliximab therapy and the development of alveolitis in this case, raises the possibility that the two might be causally related. With an increasing trend towards treating moderate to severely active ulcerative colitis patients with infliximab as a rescue therapy, clinicians should be aware of this potentially serious complication.
- 24 October 2008
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 179 (4) , 597-598
Early diagnosis of bilateral sub-deltoid bursitis using clinic-based ultrasonography in a patient receiving infliximab therapy for ulcerative pouchitis
- 24 October 2008
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 179 (4) , 597-598
Early diagnosis of bilateral sub-deltoid bursitis using clinic-based ultrasonography in a patient receiving infliximab therapy for ulcerative pouchitis
- 1 June 2008
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 20 (6) , 588-589
Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis
- 1 June 2008
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 20 (6) , 588-589
Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis
- 1 December 2007
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 1 (2) , 229-231
15th United European Gastroenterology Week
- 1 December 2007
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 1 (2) , 229-231
15th United European Gastroenterology Week